- Home
- GROY vs LYEL Comparison
GROY vs LYEL Comparison
Compare GROY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- LYEL
- Stock Information
- Founded
- GROY 2020
- LYEL 2018
- Country
- GROY Canada
- LYEL United States
- Employees
- GROY N/A
- LYEL N/A
- Industry
- GROY
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- GROY
- LYEL Health Care
- Exchange
- GROY Nasdaq
- LYEL Nasdaq
- Market Cap
- GROY 206.6M
- LYEL 203.9M
- IPO Year
- GROY 2021
- LYEL 2021
- Fundamental
- Price
- GROY $1.23
- LYEL $0.58
- Analyst Decision
- GROY Strong Buy
- LYEL Sell
- Analyst Count
- GROY 4
- LYEL 2
- Target Price
- GROY $3.25
- LYEL $1.00
- AVG Volume (30 Days)
- GROY 746.6K
- LYEL 1.1M
- Earning Date
- GROY 11-04-2024
- LYEL 02-26-2025
- Dividend Yield
- GROY N/A
- LYEL N/A
- EPS Growth
- GROY N/A
- LYEL N/A
- EPS
- GROY N/A
- LYEL N/A
- Revenue
- GROY $7,764,000.00
- LYEL $63,000.00
- Revenue This Year
- GROY $282.38
- LYEL N/A
- Revenue Next Year
- GROY $110.13
- LYEL N/A
- P/E Ratio
- GROY N/A
- LYEL N/A
- Revenue Growth
- GROY 197.02
- LYEL N/A
- 52 Week Low
- GROY $1.16
- LYEL $0.55
- 52 Week High
- GROY $2.21
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- GROY 49.41
- LYEL 37.11
- Support Level
- GROY $1.20
- LYEL $0.56
- Resistance Level
- GROY $1.25
- LYEL $0.61
- Average True Range (ATR)
- GROY 0.04
- LYEL 0.04
- MACD
- GROY 0.00
- LYEL 0.01
- Stochastic Oscillator
- GROY 50.51
- LYEL 19.88
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and streaming company. It offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.